For Clinicians | MenACWY vs MenB

A Back-to-School Meningococcal Vaccine Refresher

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed and edited by Kristen Carpenter, PA-C

Fall is coming, and with that are newly minted college students heading off to live in the dorms. That means meningitis is particularly top of mind. While the disease itself isn’t seasonal, the vaccines feel like they are because this is the moment when parents and students consider them more than ever as many college forms require action with the vaccine. To add to the confusion, there are two separate vaccines, plus combination products. MenACWY is routine and MenB isn’t, exactly. And the two pentavalent products that cover both can’t be swapped for each other partway through a series.

Parents ask whether the shot their kid got at 11 still counts, and a fair number of us have to look it up before we answer. I know I do! The meningococcal schedule has been revised more than once since most of us trained, and the version we memorized had fewer moving parts.

So this is a refresher on meningitis vaccines for you: what’s routine, which products follow which, and what these vaccines don’t cover.

Which one does the college form actually require?

MenACWY, almost always.

CDC recommends MenACWY routinely for every adolescent, first dose at 11 to 12 and a booster at 16.¹ That’s what most state college-entry requirements are built around, and most of those apply to students living in on-campus housing rather than to everyone enrolled. The rules vary by state and they get revised, so check the state your student is moving to, not the one they’re leaving.

So when a family tells you “she already got the meningitis shot,” they almost always mean MenACWY, and they’re usually right that the form is handled. 

MenB is an option, not a default

So a parent will inevitably ask you in the next few weeks: “Does she need MenB too? What even is that?”

MenACWY covers four of the five serogroups that cause most disease. MenB covers the fifth. For a healthy teenager, MenB isn’t automatic. This bug gets killed by one particular part of the immune system, so when that part is missing, broken, or switched off by a medication, catching it is a much bigger deal. That’s kids without a working spleen, kids born with a gap in that defense, and anyone on eculizumab or a drug like it, which raises the risk roughly 2,000-fold.² Lab workers who handle the bacteria and anyone caught in a B outbreak, too.² All of them get MenB.

So why isn’t it routine for everyone else? Incidence is very low, and MenB gives what ACIP itself calls short-term protection.² Rare disease plus short-lived protection is a hard case for universal vaccination. Against that, serogroup B caused every US college outbreak from 2011 to 2019.³ Both of those are true at once, which is how this became a conversation instead of a rule. You and the family decide together if this vaccine is right, and ACIP calls that shared clinical decision-making.

Vaccine Schedules

This is the part that trips people up, and it’s the easiest one to miss on a records review.

There are two combination shots that cover all five serogroups in one injection: Penbraya from Pfizer and Penmenvy from GSK. 

• The MenB half has to match all the way through. Penbraya carries Pfizer’s MenB antigen, so the second MenB dose is Trumenba. Penmenvy carries GSK’s, so the second dose is Bexsero.⁴
• The two combination shots aren’t interchangeable with each other. Don’t start with one and finish with the other.⁴
• A combination shot is for the visit where the student is due for MenACWY and has already decided on MenB. It doesn’t replace the routine MenACWY schedule on its own.⁴
• MenB is two doses, 0 and 6 months, for healthy 16 to 23 year olds.² Start at 16 and the series is finished well before move-in.

So when a student turns up with a partial series, the question is which brand, not just which vaccine. If the record says “MenB” and nothing else, get the product name before you give dose two.

Why neither the shot record nor the rash rules bacterial meningitis out

Meningitis isn’t one disease. It’s inflammation of the meninges, and the causes run from enteroviruses to pneumococcus to Haemophilus influenzae type b to the occasional fungus. The shots we’ve been talking about cover exactly one of those organisms, and MenACWY covers only four of its five serogroups. “Meningitis vaccine” is a shorthand that promises a lot more than the vial delivers.

That chasm is where two kinds of false reassurance come from: the vaccine record and the rash. Neither one rules anything out.

First: “she’s vaccinated, so it can’t be meningitis.” MenACWY doesn’t cover B. No meningococcal vaccine covers pneumococcus, Hib, or any virus. And viral meningitis is the most common kind, usually self-limiting, with most people better in a week to ten days.⁵ Odds are good that what walks in to the clinic isn’t meningococcal. That’s the reassuring part, and it’s also why the shot record can’t rule anything out.

Second: the rash. In Thompson’s 2006 study of 448 children with meningococcal disease, the signs everyone watches for (rash, stiff neck, confusion) showed up at a median of 13 to 22 hours. The early ones (leg pain, cold hands and feet, off-color skin) showed up around 8 hours.⁶ What families watch for is what comes last. Know the glass test anyway, because parents ask: press a clear glass on the rash, and spots that don’t fade (petechiae and purpura) are the worrying kind. Bad thing to wait for, and harder to see on darker skin.

So instead of focusing on the symptom list when you counsel focus on the slope. A young adult who looks worse than the illness should make them look, and is worse hour to hour instead of day to day, is the one to send in.

If someone was actually exposed

Close contacts need prophylaxis fast, ideally within 24 hours. Who counts is decided by public health, not by proximity or by how worried someone is. That makes the list short to household members, roommates, and anyone directly exposed to oral secretions in the week before symptoms started. Something like a shared lecture hall or an interaction at a cash register doesn’t qualify.

Ciprofloxacin is also no longer the automatic choice. Resistant strains have been climbing since 2019, and CDC now tells health departments to prefer rifampin, ceftriaxone, or azithromycin in areas crossing two thresholds in a rolling year: two or more invasive cases caused by resistant strains, and 20% or more of cases resistant.⁷ New York went further in August 2024 and told providers to stop using cipro for this outright.⁸

Where preparation actually helps here

Most of what we do at Jase runs on a simple premise: for a short list of common, well-understood conditions, the clinical work can happen before the patient needs it, so nobody is sorting it out alone at 11pm. That’s what we mean by appropriate medical preparation.

Meningitis is where that premise stops. There’s no kit for this one. The preparation that helps a college student is a complete vaccination record and a low threshold for the ER when worrying symptoms appear.And nobody should be dosing themselves out of a standby antibiotic supply after a campus scare, a Jase kit included. That skips the resistance picture that decides the right drug, and it skips the contact tracing that decides whether they need anything at all.

We’re here for the times when primary care isn’t there, and this isn’t one of them. We’ll keep publishing where we draw these lines.

The bottom line

MenACWY is routine at 11 to 12 with a booster at 16, and it’s what the college form is asking about. MenB is a separate two-dose series under shared clinical decision-making, unless your patient is one of the people who gets it routinely. Brands don’t mix, so get the product name before dose two. And a shot record doesn’t rule meningitis out. When the slope is hours instead of days, that’s the ER.

Sources

1. CDC. Meningococcal vaccine recommendations for healthcare providers. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html
2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(RR-9):1-41. https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
3. Marshall GS, Dempsey AF, Srivastava A, Isturiz RE. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. J Pediatric Infect Dis Soc. 2019;9(2):244-247. https://pmc.ncbi.nlm.nih.gov/articles/PMC7192401/
4. CDC. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2025. MMWR. 2026;75(1). https://www.cdc.gov/mmwr/volumes/75/wr/mm7501a2.htm
5. CDC. About Viral Meningitis. https://www.cdc.gov/meningitis/about/viral-meningitis.html
6. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. https://pubmed.ncbi.nlm.nih.gov/16458763/
7. Berry I, Rubis AB, Howie RL, et al. Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance, United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(5):99-103. https://www.cdc.gov/mmwr/volumes/73/wr/mm7305a2.htm
8. New York State Department of Health. State directs providers to discontinue use of ciprofloxacin to prevent meningococcal disease due to increasing antimicrobial resistance. August 14, 2024. https://www.health.ny.gov/press/releases/2024/2024-08-14_ciprofloxacin.htm

For Clinicians | Strep Throat vs. Sore Throat

Do You Need Antibiotics?

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed and edited by Kristen Carpenter, PA-C

Most sore throats don’t need an antibiotic. Most of us already know that.

What’s harder to keep straight is the one patient who does, and what happens if that visit gets waved through like all the others. A kid with a sore throat, no cough, tender glands, running a fever, looks almost exactly like the kid down the hall with a garden-variety virus. The difference matters for antibiotic stewardship and, more importantly, for their health. Untreated Group A strep can progress to rheumatic fever: permanent heart valve damage that can show up weeks after the sore throat is long forgotten. Rheumatic fever is rare enough in the US that a lot of us learned about it as a historical disease that isn’t around anymore. But, it isn’t gone. It’s just rare enough, and quiet enough, that it’s easy to lose track of why the testing and treatment ritual around strep exists.

Today we’re talking about the tool that resolves that tension: the Centor score (McIsaac-modified for kids), what it tells you, and why the treatment on the other side of a positive test hasn’t changed in decades.

Do you need antibiotics for a sore throat?

Most of the time, no. The majority of sore throats, especially in adults, are viral. As you know antibiotics don’t affect a virus, and prescribing one anyway doesn’t get the patient better faster. It just adds an unnecessary drug, and an unnecessary risk, to their day. And contributes to antimicrobial resistance.

But roughly 5-15% of adult sore throats, and 20-30% of pediatric cases, are Group A strep. Symptom judgment alone doesn’t reliably separate the two: exudate can show up with mono, fever can show up with either, and “it just looks bad” isn’t a diagnostic criterion. The actual clinical problem isn’t “treat everyone” versus “treat no one.” It’s how to tell, reliably, which patient in front of you is which.

The four-question tool: the Centor score

The Centor score, McIsaac-modified with an age adjustment, turns that judgment call into a short checklist:

• Tonsillar exudate
• Tender anterior cervical lymphadenopathy
• Absence of cough
• History of fever
• Age adjustment: add a point for ages 3-14, subtract a point for ages 45 and up

Add it up. The score runs from -1 to 5, and each end points to a different action. A score of 0 or below means under 10% odds of an actual GAS infection: treat it as viral, skip testing. A score of 4 or 5 means over 50% odds: test to confirm if you want, but treating before the result comes back is reasonable. Everything in between, 1 through 3, is the test-before-you-decide zone, where a rapid strep swab settles it.

Take a 52-year-old with a cough, no exudate, no tender nodes, and no fever: zero criteria met, minus one for age 45 and up, for a total score of -1, the bottom of the range. Skip testing. Now take an 8-year-old with exudate, tender anterior cervical nodes, no cough, and a fever: four criteria met, plus one for age 3-14, for a total score of 5, the top of the range. Test and likely treat.

Using this little checklist in practice cuts unnecessary initial antibiotic prescribing by close to half, without missing the strep infections that matter. It settles the question directly: which patient in front of you actually needs the prescription.

When to test, and when the rapid test needs backup

A score in the test-before-you-decide zone (1 through 3) means swab and run a rapid antigen detection test (RADT). 

• Positive RADT: treat. No backup culture needed, in adults or kids. The test’s specificity is high enough to act on directly.
• Negative RADT in children and adolescents: back it up with a throat culture before ruling out strep. RADT sensitivity isn’t perfect, and this is the population carrying most of the rheumatic fever risk.
• Negative RADT in adults: no backup culture needed. The downstream risk is low enough that a negative result can stand on its own.

In practice, a lot of this happens before you’re even in the room. Plenty of practices swab everyone with a sore throat during rooming now, since newer RADT platforms turn around a result in about 15 minutes, often faster than the visit itself. That’s fine: RADT specificity is high enough that a positive result still means treat, even in a patient who scored a 0 and never should have been swabbed by the letter of the algorithm. The score’s real job in that kind of workflow isn’t gatekeeping who gets tested. It’s telling you how much to trust a negative, and in whom.

Why penicillin, still, after all these years

Once you’ve got a positive result, the treatment hasn’t changed: penicillin V or amoxicillin for a full 10 days. Group A strep has never developed resistance to penicillin. Which is impressive since clinicians have been prescribing it for decades for this. There’s no clinical reason to reach for a macrolide or a cephalosporin here unless the patient has a true penicillin allergy.

The full 10 day course really does matter too. The rheumatic fever prevention data behind this whole guideline was built on the 10-day course, not a shorter one, and stopping early is still the most common way an adequately-treated strep infection turns into a recurrence.

The bottom line

Most sore throats are viral, and most clinicians already know not to reach for the prescription pad on symptoms alone. The Centor score turns that instinct into a number: four questions that tell you which patient is worth testing, and which one just needs reassurance and time. When the test comes back positive, the treatment hasn’t changed in decades: penicillin or amoxicillin for the full 10 days.

We built Jase on that same idea: don’t guess who needs antibiotics, use a real framework to decide. Appropriate medical preparation takes the same logic behind the Centor score, defined criteria instead of a feeling, and applies it earlier: deciding ahead of time which predictable, self-limiting conditions are safe to prepare for before symptoms even start. In no way a replacement for a clinician’s judgment call. Just that same judgment, applied sooner.

Sources

1. Centor RM, Witherspoon JM, Dalton HP, Brody CE, Link K. The Diagnosis of Strep Throat in Adults in the Emergency Room. Medical Decision Making. 1981;1(3):239-246.
2. McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998;158(1):75-83.
3. Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2012;55(10):e86-e102.
4. CDC. Clinical Guidance for Group A Streptococcal Pharyngitis.
5. Hamilton JL, McCrea L. Streptococcal Pharyngitis: Rapid Evidence Review. American Family Physician. 2024;109(4):343-349.
6. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association. Circulation. 2009;119(11):1541-1551.